Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: Nested case-control study based on UK General Practice Research Database

BMJ

Volumn 342, Issue 7804, 2011, Pages

  Parkin, Lianne ^a   Sharples, Katrina ^a   Hernandez, Rohini K ^b   Jick, Susan S ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DROSPIRENONE; LEVONORGESTREL; ANDROSTANE DERIVATIVE; ESTROGEN; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CASE CONTROL STUDY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; NON FATAL IDIOPATHIC VENOUS THROMBOEMBOLISM; ORAL CONTRACEPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; UNITED KINGDOM; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANDROSTENES; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL; CONTRACEPTIVES, ORAL, COMBINED; ESTROGENS; FEMALE; GREAT BRITAIN; HUMANS; LEVONORGESTREL; RISK FACTORS; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 79955549397     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d2139     Document Type: Article

References (28)

1. Sheldon T. Dutch GPs warned against new contraceptive pill. BMJ 2002;324:869.
2. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995;346:1582-8.
3. Jick H, Jick SS, Gurewich V, Wald Myers M, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolismin women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589-93. (Pubitemid 26001840)
4. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995;346:1593-6. (Pubitemid 26001841)
5. Jick H, Kaye JA, Vasilakis-Scaramozza C, Jick SS. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ 2000;321:1190-5.
6. Parkin L, Skegg DCG, Wilson M, Herbison GP, Paul C. Oral contraceptives and fatal pulmonary embolism. Lancet 2000;355:2133-4. (Pubitemid 30364664)
7. Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 2001;358:1427-9. (Pubitemid 33055749)
8. Seeger JD, Loughlin J, Eng PM, Clifford CR, Cutone J, Walker AM. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet Gynecol 2007;110:587-93. (Pubitemid 47359582)
9. Dinger JC, Heinemann LAJ, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 2007;75:344-54.
10. Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009;339:b2890.
11. Van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJM, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009;339:b2921.
12. Jick H, Garcia-Rodriguez LA, Perez-Gutthann S. Principles of epidemiological research on adverse and beneficial drug effects. Lancet 1998;352:1767-70. (Pubitemid 28534970)
13. Rothman KJ, Pool C. A strengthening programme for weak associations. Int J Epidemiol 1988;17:955-9. (Pubitemid 19042043)
14. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995;346:1575-82.
15. Winter M, Keeling D, Sharpen F, Cohen H, Vallance P, for the Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Procedures for the outpatient management of patients with deep venous thrombosis. Clin Lab Haem 2005;27:61-6.
16. Van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res 2007;16:219-42.
17. Raghunathan T, Lepkowski J, Hoewyk J, Solenberger P. Amultivariate technique for multiply imputing missing values using a sequence of regression models. Surv Methodol 2001;27:85-95.
18. Royston P. Multiple imputation of missing values: update of ice. Stata J 2005;5:527-36. (Pubitemid 43708457)
19. Sterne JAC, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 2009;338:b2393.
20. Episheet. Spreadsheets for the analysis of epidemiologic data [program]. Episheet, 2005.
21. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001;323:131-4. (Pubitemid 32678382)
22. Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 2011;340:d2151.
23. Van Vliet HAAM, Winkel TA, Noort I, Rosing J, Rosendaal FR. Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate. J Thromb Haemost 2004;2:2060-2. (Pubitemid 40192767)
24. Tchaikovski SN, van Vliet HAAM, Thomassen MCLGD, Bertina RM, Rosendaal FR, Morten Sandset P, et al. Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography. Thromb Haemost 2007;98:1350-6. (Pubitemid 350239109)
25. Maitra NN, Kulier R, Bloemenkamp K, Helmerhorst FM, Gulmezoglu AM. Progestogens in combined oral contraceptives for contraception. Cochrane Database Syst Rev 2009;1:CD004861.
26. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA, Garner SE. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2009;1:CD004425.
27. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2009;1:CD006586.
28. Gallo MF, Lopez LM, Grimes DA, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2009;1:CD003987.